Showing 1 to 2 of 2 results


NIH's $1.8 Billion Long COVID Investment: Slow Progress Fuels Patient Frustration
The NIH has invested $1.8 billion in long COVID research, yet millions of patients lack effective treatments, prompting calls for faster clinical trials and FDA approvals; research focuses on understanding the disease's mechanisms before large-scale trials.
NIH's $1.8 Billion Long COVID Investment: Slow Progress Fuels Patient Frustration
The NIH has invested $1.8 billion in long COVID research, yet millions of patients lack effective treatments, prompting calls for faster clinical trials and FDA approvals; research focuses on understanding the disease's mechanisms before large-scale trials.
Progress
60% Bias Score

New Treatments for Non-Communicable Diseases Launched in Uganda
C&D Pharma launches three innovative treatments for non-communicable diseases in Uganda with support from the Ministry of Health and other partners.

New Treatments for Non-Communicable Diseases Launched in Uganda
C&D Pharma launches three innovative treatments for non-communicable diseases in Uganda with support from the Ministry of Health and other partners.
Progress
0% Bias Score
Showing 1 to 2 of 2 results